MONDAY, JUNE 18, 2018

Valneva unveils two recent EB66 agreements

Valneva unveils two recent EB66 agreements.
Valneva unveils two recent EB66 agreements. | Courtesy of
Valneva recently announced that it has signed two new EB66 agreements with Kaketsuken, which is a Japanese pharmaceutical company, and Fatro, an Italian firm.

Valneva has already signed a total of seven new deals for EB66, a pandemic flu vaccine, since the start of 2015. The company expects that it will sign even more agreements throughout the second half of this year.

All of the license agreements are solely dedicated to the company’s new EB66 cell line, which is for veterinary and human vaccines that are currently under development.

Valneva officials have reported that they estimate Kaketsuken to be the first that will earn a stockpiling contract for the new vaccine.

"The EB66 cell line has proven its performance in the development of both veterinary and human vaccines with the marketing approval of three new EB66-based vaccines in 2014 in three different regions of the world at a time when the regulatory environment is very demanding,” President and CEO Thomas Lingelbach and Valneva Deputy CEO Franck Grimaud said. “The industry is becoming increasingly aware that the half-century-old egg-based method of producing vaccines has major limitations and some of the world's largest pharmaceutical companies have already found in Valneva's EB66 technology an excellent replacement for egg-based vaccine production."

Organizations in this Story


Want to get notified whenever we write about Valneva ?
Next time we write about Valneva, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.